CTLA4 and inflammatory bowel disease: Based on these findings, alternative drugs can be considered in place of anti-CTLA-4 monoclonal antibodies, in combination with anti-PD1, to downregulate irAEs associated with IBD and potentially enhance the anti-tumor effects.